Boehringer reports first data for IL-36R inhibitor in rare type of psoriasis

Boehringer said BI 655130 cleared symptoms of generalized pustular psoriasis within one week in a Phase I trial in seven patients experiencing an acute moderate-to-severe flare of the disease. BI 655130 is a mAb against IL-36R.

Boehringer Ingelheim GmbH (Ingelheim, Germany) said there are no FDA-approved therapies for generalized pustular psoriasis...